BioTime, Inc. (BTX) - Medical Equipment - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence

BioTime, Inc. (BTX) - Medical Equipment - Deals and Alliances Profile

BioTime, Inc. (BTX) - Medical Equipment - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence
BioTime, Inc. (BTX) - Medical Equipment - Deals and Alliances Profile
Published Oct 18, 2016
78 pages — Published Oct 18, 2016
Price US$ 250.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

BioTime, Inc. (BioTime) is a biotechnology company with focus on regenerative medicine and plasma volume expanders. The companys Hextend is a blood plasma volume expander used for the treatment of hypovolemia in surgery, emergency trauma treatment, and other applications. The company is also developing Renevia to facilitate cell transplantation; AST-VAC1 autologous (patient-specific) cancer vaccine; Premvia for tendon and wound-management applications; OpRegen for the treatment of dry form of age-related macular degeneration (AMD); AST-OPC1 for spinal cord injury rehabilitation; HyStem hydrogel products; and mobile health software products.

BioTime, Inc. (BTX) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical Equipment eTrack deals database, and primary and secondary research.


Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.


Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals include

  
Source:
Document ID
GDME225D
Country
Industry
Ticker
Company
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
BioTime, Inc., Medical Equipment, Deals By Year, 2010 to YTD 201652
BioTime, Inc., Medical Equipment Deals By Type, 2010 to YTD 201671
BioTime, Inc., Medical Equipment, Deals By Region, 2010 to YTD 201681
BioTime, Inc., Medical Equipment, Deals By Market, 2010 to YTD 201691
BioTime, Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016102
BioTime, Inc., Medical Equipment, Deal Details1230
  Venture Financing121
    LifeMap Solutions Raises US$5 Million In Seed Financing121
    Glycosan BioSystems Raises US$0.6 Million In Venture Financing131
  Partnerships141
    OncoCyte Enters into Licensing Agreement with Cornell University for PanC-Dx141
    OncoCyte Enters into Co-Development Agreement with Abcodia for PanC-Dx Test151
    OncoCyte Expands Co-Development Agreement with Wistar Institute161
    BioTime Enters Into Distribution Agreement With USCN Life Science171
    OncoCyte Enters into Licensing Agreement with Wistar Institute of Anatomy and Biology182
    Heraeus Medical Enters into Licensing Agreement with OrthoCyte201
    Biotime Amends Licensing Agreement With University of Utah211
    BioTime Enters Into Option Licensing Agreement With USCN Life Science221
  Equity Offering231
    OncoCyte Raises USD3.2 Million in Private Placement of Units232
    OncoCyte Raises USD7.3 Million in Private Placement of Units251
    BioTime Raises USD5 Million in Private Placement of Shares262
    OncoCyte Raises USD3.3 Million in Private Placement of Shares281
    BioTime Completes Private Placement Of Shares For US$6.4 Million291
    BioTime Announces Public Offering Of Shares For Up To US$15 Million301
    BioTime Completes Public Offering Of Shares For US$3.5 Million311
    BioTime Completes Private Placement Of Units For US$9 Million322
    BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million342
    BioTime Announces Private Placement Of Common Stock361
    BioTime Completes Private Placement For US$3.6 Million371
  Acquisition381
    OrthoCyte Completes Acquisition Of Glycosan BioSystems382
    BioTime Acquires ES Cell International402
BioTime, Inc. - Key Competitors421
Key Employees431
Locations And Subsidiaries442
  Head Office441
  Other Locations &Subsidiaries442
Recent Developments461
Financial Announcements461
Aug 09, 2016: BioTime Reports Second Quarter Results and Recent Corporate Accomplishments462
May 10, 2016: BioTime Reports First Quarter Results and Recent Corporate Accomplishments483
Nov 09, 2015: BioTime Reports Third Quarter 2015 Results and Recent Corporate Accomplishments514
Aug 10, 2015: BioTime Reports Second Quarter 2015 Results and Recent Developments553
May 11, 2015: BioTime Reports First Quarter 2015 Results and Recent Corporate Accomplishments582
May 07, 2015: Asterias Biotherapeutics Reports First Quarter Results601
Mar 11, 2015: BioTime Reports Fourth Quarter and Fiscal Year End 2014 Financial Results and Recent Corporate Accomplishments612
Corporate Communications631
Dec 30, 2015: BioTime Announces When-Issued Trading of Subsidiary OncoCyte in Connection With Planned Distribution631
Nov 18, 2015: BioTime Announces the Appointment of Life Sciences Industry Veteran Russell Skibsted as Chief Financial Officer641
Oct 19, 2015: Adi Mohanty Joins Michael D. West, PhD, as Co-CEO of BioTime651
Sep 14, 2015: BioTime Subsidiary OncoCyte Appoints Cavan Redmond to its Board of Directors661
Jun 16, 2015: William Annett Named Chief Executive Officer of OncoCyte671
Jan 12, 2015: BioTime Subsidiary OncoCyte Appoints William Annett to Its Board of Directors681
Product News691
Apr 20, 2015: OncoCyte Announces Initial Data From Ongoing Clinical Study of Collagen Type X as a Marker and Potential Diagnostic for Breast Cancer and Other Types of Human Cancers691
Apr 20, 2015: Positive Clinical Results of OncoCyte s PanC-Dx Diagnostic Test Demonstrate High Level of Sensitivity and Specificity in Non-Invasive Detection of Bladder Cancer701
Mar 20, 2015: OncoCyte Announces Availability of Abstracts With New Clinical Data From Studies of PanC-Dx Cancer Diagnostic in Bladder711
Mar 20, 2015: OncoCyte Announces Availability of Abstracts With New Clinical Data From Studies of PanC-Dx Cancer Diagnostic in Breast Cancer721
Feb 24, 2015: BioTime Announces First Patient Treated in Pivotal Clinical Trial of Renevia for HIV-Associated Lipoatrophy732
Clinical Trials751
Feb 24, 2015: BioTime Announces First Patient Treated in Pivotal Clinical Trial of Renevia for HIV-Associated Lipoatrophy752
Other Significant Developments771
Jan 27, 2015: ESI BIO - A Division of BioTime Announces New UK Distribution Agreement with 2BScientific771
Appendix781
  Methodology781
  About GlobalData781
  Contact Us781
  Disclaimer781

Table Of Contents

About the Author


Cite this Report

  
MLA:
GlobalData Financial Mergers and Acquisitions Intelligence. "BioTime, Inc. (BTX) - Medical Equipment - Deals and Alliances Profile" Oct 18, 2016. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/BioTime-Inc-BTX-Medical-Equipment-Deals-and-Alliances-Profile-2148-5579>
  
APA:
GlobalData Financial Mergers and Acquisitions Intelligence. (2016). BioTime, Inc. (BTX) - Medical Equipment - Deals and Alliances Profile Oct 18, 2016. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/BioTime-Inc-BTX-Medical-Equipment-Deals-and-Alliances-Profile-2148-5579>
  
US$ 250.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research